Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort
Open Access
- 2 March 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 30 (5), 982-989
- https://doi.org/10.1158/1055-9965.epi-19-0580
Abstract
Background: Hyperinsulemia and glycemic control may play a role as prostate cancer prognostic factors, whereas use of certain antidiabetic drugs, that is metformin, could improve the prognosis. We examined the link between antidiabetic medication use and prostate cancer survival taking into account simultaneous use of multiple drugs. Methods: The study cohort composed of 6,537 men in The Finnish Randomized Study of Screening for Prostate Cancer with prostate cancer diagnosed 1996 to 2009. Use of medication was attained from the nationwide prescription database of the Social Insurance Institution of Finland. Median follow-up was 9.2 years postdiagnosis. A total of 1,603 (24,5%) men had used antidiabetic medication. A total of 771 men died of prostate cancer during the follow-up. We used multivariable-adjusted Cox regression to evaluate the risk of prostate cancer death and onset of androgen deprivation therapy (ADT) with adjustment for prostate cancer clinical characteristics, comorbidities and use of other drugs. Separate analyses were further adjusted for blood glucose. Results: Risk of prostate cancer death was higher among antidiabetic drug users overall (HR = 1.42; 95% CI, 1.18–1.70) compared with nonusers, separately among insulin and metformin users. Adjustment for blood glucose level abolished the risk increase. Risk of ADT initiation was increased among the medication users (HR = 1.26; 95% CI, 1.05–1.49). Conclusions: Men with prostate cancer using antidiabetic medication are generally at increased risk of dying from prostate cancer compared with nonusers. The risk association is driven by underlying diabetes, as adjustment for blood glucose level ameliorates the risk increase. Impact: Type 2 diabetes should be considered as a risk factor when considering prostate cancer prognosis.Funding Information
- Pirkanmaan Sairaanhoitopiiri (9X032)
This publication has 24 references indexed in Scilit:
- Prostate Cancer Mortality in the Finnish Randomized Screening TrialJNCI Journal of the National Cancer Institute, 2013
- Why are diabetics at reduced risk for prostate cancer? A review of the epidemiologic evidenceUrologic Oncology, 2012
- Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patientsAnnals of Oncology, 2011
- The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy seriesCancer Causes & Control, 2011
- A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians †Human Molecular Genetics, 2010
- Serum Insulin, Glucose, Indices of Insulin Resistance, and Risk of Prostate CancerJNCI Journal of the National Cancer Institute, 2009
- Metformin use and prostate cancer in Caucasian men: results from a population-based case–control studyCancer Causes & Control, 2009
- Diabetes mellitus and risk of prostate cancer in the health professionals follow‐up studyInternational Journal of Cancer, 2008
- Antidiabetic Medication and Prostate Cancer Risk: A Population-based Case-Control StudyAmerican Journal of Epidemiology, 2008
- Assessment of causes of death in a prostate cancer screening trialInternational Journal of Cancer, 2007